35090-65-4

Basic information

• Product Name: 6-bromo-2-hydroxy-3-methoxybenzyl alcohol
• Synonyms: 6-bromo-2-hydroxy-3-methoxybenzyl alcohol
• CAS NO: 35090-65-4
• Molecular Weight: 233.062
• Mol File: 35090-65-4.mol

Chemical Properties

• CAS DataBase Reference: 6-bromo-2-hydroxy-3-methoxybenzyl alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-2-hydroxy-3-methoxybenzyl alcohol(35090-65-4)
• EPA Substance Registry System: 6-bromo-2-hydroxy-3-methoxybenzyl alcohol(35090-65-4)

Safety Data

• Hazardous Substances Data: 35090-65-4(Hazardous Substances Data)

Upstream product

• 20035-41-0 6-bromo-2-hydroxy-3-methoxybenzaldehyde 

Downstream Products

• 852608-71-0 7-methoxy-2-(4-trifluoromethyl-phenyl)-benzofuran-4-carbaldehyde 
• 852608-67-4 7-methoxy-2-(2-trifluoromethyl-phenyl)-benzofuran-4-carbaldehyde 
• 852608-56-1 7-methoxy-2-(2-methoxy-phenyl)-benzofuran-4-carbaldehyde 
• 852608-64-1 2-(3-fluoro-phenyl)-7-methoxy-benzofuran-4-carbaldehyde 
• 852608-60-7 7-methoxy-2-(4-methoxy-phenyl)-benzofuran-4-carbaldehyde 
• 852608-62-9 2-(2-fluoro-phenyl)-7-methoxy-benzofuran-4-carbaldehyde 
• 852608-58-3 7-methoxy-2-(3-methoxy-phenyl)-benzofuran-4-carbaldehyde 
• 852608-65-2 2-(4-fluoro-phenyl)-7-methoxy-benzofuran-4-carbaldehyde 

Relevant articles and documents

ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT

The present invention provides a novel isoquinoline derivative which is useful as a pharmaceutical agent having a phosphodiesterase inhibitory activity. The isoquinoline derivative of the present invention is represented by the following general formula (

HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT

Novel heterocyclic biaryl derivatives were disclosed which are useful as pharmaceutical agents and which exhibit a phosphodiesterase-inhibitory action. The heterocyclic biaryl derivatives are represented by the following general formula (1): wherein the H

PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyridazinone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1 represents H or C1-6 alkyl, each of R2 and R3 represents H, X, C1-6 alkoxy, Z represents O or S, and A represents AA or BB, wherein AA represents: and BB represents: wherein R4 represents H or C1-6 alkyl, and each of R5 and R6 represents C1-6 alkyl.

PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyrazolone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1,R2: C1-6 alkyl; R3,R4: H, X, C1-6 alkoxy; Z:O, S; A:AA, BB, wherein AA represents wherein BB represents wherein R5: H, C1-6 alkyl ; R6,R7: C1-6 alkyl.

Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective α2C-adrenergic receptor antagonists

The synthesis of a series of 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-2-arylbenzofuran and 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran-2-carboxamide derivatives as novel α2C-adrenergic receptor antagonists are described. Their affinity at three different human α2-adrenergic receptors is reported, and some of these compounds exhibited high affinity for the α2C-adrenergic receptor with high subtype selectivity. Among them, compound 10e has been found to show the anti-l-dopa-induced dyskinetic activity in marmosets. The structure-activity relationship of these compounds is also discussed.